von Willebrand disease (VWD): evidence‐based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA)1
Top Cited Papers
Open Access
- 28 February 2008
- journal article
- practice guideline
- Published by Wiley in Haemophilia
- Vol. 14 (2), 171-232
- https://doi.org/10.1111/j.1365-2516.2007.01643.x
Abstract
Summary. von Willebrand disease (VWD) is a commonly encountered inherited bleeding disorder affecting both males and females, causing mucous membrane and skin bleeding symptoms, and bleeding with surgical or other haemostatic challenges. VWD may be disproportionately symptomatic in women of child‐bearing age. It may also occur less frequently as an acquired disorder (acquired von Willebrand syndrome). VWD is caused by deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates platelet haemostatic function and stabilizes blood coagulation factor VIII. The pathophysiology, classification, diagnosis and management of VWD are relatively complex, but understanding them is important for proper diagnosis and management of patients with VWD. These evidence‐based guidelines for diagnosis and management of VWD from the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel (USA) review relevant publications, summarize current understanding of VWD pathophysiology and classification, and present consensus diagnostic and management recommendations based on analysis of the literature and expert opinion. They also suggest an approach for clinical and laboratory evaluation of individuals with bleeding symptoms, history of bleeding or conditions associated with increased bleeding risk. This document summarizes needs for further research in VWF, VWD and bleeding disorders, including clinical research to obtain more objective information about bleeding symptoms, advancements in diagnostic and therapeutic tools, and enhancement in the education and training of clinicians and scientists in bleeding and thrombotic disorders. The NHLBI Web site (http://www.nhlbi.nih.gov/guidelines/vwd) has a more detailed document, a synopsis of these recommendations, and patient education information.Keywords
This publication has 372 references indexed in Scilit:
- An association of candidate gene haplotypes and bleeding severity in von Willebrand disease type 2A, 2B, and 2M pedigreesJournal of Thrombosis and Haemostasis, 2005
- Type 3 von Willebrand disease: assessment of complications and approaches to treatment – results of a patient and Hemophilia Treatment Center Survey in the United StatesHaemophilia, 2004
- Comparison of Two von Willebrand Factor Collagen-Binding Assays with Different Binding Affinities for Low, Medium, and High Multimers of von Willebrand FactorSeminars in Thrombosis and Hemostasis, 2002
- Summary of a workshop on potency and dosage of von Willebrand factor concentratesHaemophilia, 1998
- Characterization of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand factor multimer analysisHaemophilia, 1998
- Recurrent haemoperitoneum in a female patient with type III von Willebrand’s disease responded to administration of oral contraceptiveHaemophilia, 1998
- Management of abnormal uterine bleedingAmerican Journal of Obstetrics and Gynecology, 1996
- Prevalence of von Willebrand disease in children: A multiethnic studyThe Journal of Pediatrics, 1993
- Platelet Aggregation Induced by I-Desamino-8-D-Arginine Vasopressin (dDAVP) in Type IIb von Willebrand's DiseaseThe New England Journal of Medicine, 1983
- Incidence of Severe von Willebrand's DiseaseThe New England Journal of Medicine, 1982